There has been a significant increase in electronic cigarette (e-cigarette) use since its introduction in 2007. Ironically, there remains very few published literature on the respiratory complications of e-cigarettes. The use of personalized vaporizers or commonly known as “vaping” has started to overtake standard e-cigarette. Its dynamic vaporizer customization makes it challenging to assess long-term health effects. Case reports on the pulmonary complications of e-cigarettes are limited to bronchiectasis, eosinophilic pneumonia, pleural effusion, and suspected hypersensitivity pneumonitis. Diffuse alveolar hemorrhage (DAH) is bleeding into the alveolar spaces of the lung secondary to disruption of the alveolar-capillary basement membrane. We report a case of young male presenting with subacute respiratory failure. He was later found to have diffuse alveolar hemorrhage syndrome that is likely induced by aggressive vaping. This adds up to the rising concern on the possible serious complications of this innovative technology designed as a safer alternative to traditional cigarettes.
Electronic cigarettes (e-cigarettes) were initially marketed in 2007 and since then there had been a steady growth of its use amongst naive and chronic smokers . “Vapor” is the aerosol inhaled through heating a liquid in the device . Nowadays, personal vaporizers or “vape” are considered a step-up from the standard e-cigarette. Its popularity is mainly driven by the ability for device customization. Users can mix and match liquids to achieve preferred flavor and cloud production.
To date, there still varied results on how e-cigarette affects smoking cessation [3–5]. Whether or not the efficacy of e-cigarettes for assisting smoking cessation becomes established, its safety profile and health related risks warrant extensive evaluation. The dynamic device design makes it difficult to perform calculations of the harm compared with conventional cigarette smoking .
There exists very few reported cases of pulmonary complications of e-cigarettes and these are limited to hypersensitivity inhalational injury, pneumonitis, and acute eosinophilic pneumonia . We report a case of diffuse alveolar hemorrhage that we believe was caused by aggressive use of personalized vaporizer. This aims to site the serious complication of vaping despite being marketed as a safe substitute to conventional smoking.
2. Case Presentation
Thirty-three-year-old male with diabetes and seizure disorder presented to the emergency department (ED) with worsening dyspnea and hemoptysis. Two weeks prior to his ED presentation, he was treated with antibiotics for community acquired pneumonia with minimal improvement. Upon further inquiry, patient admitted to vaping for the past 2 months with overtly increased exposure time and has experimented on new flavors. He denied previous or current recreational drug use. CT scan of the chest showed diffuse ground glass opacities and bilateral patchy consolidation (Figure 1(a)). He had worsening hypoxia that required noninvasive ventilation. His echocardiogram was otherwise normal. Bronchoscopic examination failed to demonstrate airway lesions. Bronchoalveolar lavage (BAL) revealed increasing blood in four sequential aliquots confirming diagnosis of DAH (Figure 2). BAL cell count showed greater than 30,000 RBCs and 800 WBCs, 42% neutrophils, 36% lymphocytes, 1% eosinophils, and 21% macrophages. All inflammatory serologies were unremarkable: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), antinuclear antibody (ANA), and anti-antineutrophil cytoplasmic antibodies (ANCA). In addition, serum eosinophil count, anti-glomerular basement membrane (GBM) antibodies, and anti-phospholipid antibodies were all normal. Urine toxicology screen which includes amphetamines, cannabinoids, and cocaine was negative. There was no microbiologic growth on all BAL specimens. Patient was treated with pulse dose steroids after DAH was confirmed with BAL aliquots (Figure 2). He underwent right wedge resection lung biopsy which revealed evidence of bland pulmonary hemorrhage (Figure 3(a)) with no evidence of capillaritis or diffuse alveolar damage (DAD). Prussian blue iron staining was also noted which reflects old hemorrhage (Figure 3(b)). His symptoms improved with complete resolution of alveolar hemorrhage on chest CT scan after 2 weeks (Figure 1(b)). His steroids were tapered quickly and he has not used a personal vaporizer since then.
The use of personalized vaporizers or vaping has exponentially increased replacing standard e-cigarettes. It has attracted young adults as they can customize and reuse their vaporizers making it a cheaper alternative. While vaping is likely less toxic than cigarette smoking given the lack of most combustible tobacco constituents, we are still uncertain on the health hazards of the reduced toxins. The rapidly changing designs of the product and the lack of long-term follow-up make assessment on the risk of health challenging .
There are a few published reports on the respiratory complications of e-cigarettes. These are limited to bronchiectasis, eosinophilic pneumonia, pleural effusion, and suspected hypersensitivity pneumonitis [7, 8]. Biopsy-proven Respiratory Bronchiolitis Interstitial Lung Disease (RBILD) has been demonstrated with e-cigarette use in one case report . Atypical pneumonitis evidenced by bronchoalveolar lavage analysis and lipid staining has also been reported. The syndrome of diffuse alveolar hemorrhage is caused by injury or inflammation of the arterioles, venules, or alveolar capillaries. DAH is often a catastrophic clinical syndrome causing respiratory failure. The etiology of DAH is multifactorial and can be divided into three categories, namely, pulmonary capillaritis, bland alveolar hemorrhage, and diffuse alveolar damage (DAD) . Recognition of DAH often requires BAL analysis as symptoms are nonspecific. Hemoptysis is absent in up to one-third of patients, and radiographic imaging is also nonspecific and similar to other acute alveolar filling processes [10, 11]. Lung biopsy is often required to establish definite pathologic pattern.
Cases relating to smoking-induced DAH are limited to few reports on cocaine and cannabis use [12, 13]. We postulate that direct exposure to inhalation products of heated liquid resulted to alveolar injury. The exposure may or may not elicit alveolar inflammation. Although cell culture and experimental animal data indicate that e-cigarette have the potential for inducing inflammation, this still remains unclear on human studies . The e-juice used in this case had a predominant base of propylene glycol (PG) in addition to nicotine, water, and 2 artificial flavorings. The temporal relations of patient’s aggressive vaping and the development of alveolar hemorrhage remain circumstantial. However, we are unaware of any other explanation for the patient’s bland pulmonary hemorrhage. Cessation of implicated exposure and supportive care are core treatments of DAH. Immunosuppressive medication is added if there is histologic evidence of capillaritis. In our case, it is challenging to determine if the improvement of patient’s symptoms and radiographic findings were related to discontinuation of exposure to vapor or the effect of steroids. Pulse steroids were initiated early in our patient as his hypoxia continued to worsen. This was tapered quickly as soon as inflammatory makers showed negative results. Our initial aggressive treatment was geared to decrease the high morbidity and mortality associated with DAH. In conclusion, severe complication may arise from vaping despite being marketed as a safe alternative to conventional smoking. This would encourage clinicians to be vigilant on the respiratory risks of vaping. Likewise, this should also encourage more research on the pulmonary toxicity of vaping as the surge of its use continues in the coming years.
1. McMillen R. C., Gottlieb M. A., Whitmore Shaefer R. M., Winickoff J. P., Klein J. D. Trends in electronic cigarette use among U.S. adults: Use is increasing in both smokers and nonsmokers. Nicotine & Tobacco Research. 2015;17(10):1195–1202. doi: 10.1093/ntr/ntu213. [PubMed] [CrossRef] [Google Scholar]2. Brown C. J., Cheng J. M. Electronic cigarettes: product characterisation and design considerations. Tobacco Control. 2014;23(suppl 2):ii4–ii10. doi: 10.1136/tobaccocontrol-2013-051476. [PMC free article] [PubMed] [CrossRef] [Google Scholar]3. Orr K. K., Asal N. J. Efficacy of electronic cigarettes for smoking cessation. Annals of Pharmacotherapy. 2014;48(11):1502–1506. doi: 10.1177/1060028014547076. [PubMed] [CrossRef] [Google Scholar]4. Kalkhoran S., Glantz S. A. E-cigarettes and smoking cessation in real-world and clinical settings: A systematic review and meta-analysis. The Lancet Respiratory Medicine. 2016;4(2):116–128. doi: 10.1016/S2213-2600(15)00521-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]5. El Dib R., Suzumura E. A., Akl E. A., et al. Electronic nicotine delivery systems and/or electronic non-nicotine delivery systems for tobacco smoking cessation or reduction: A systematic review and meta-analysis. BMJ Open. 2017;7(2) doi: 10.1136/bmjopen-2016-012680.e012680 [PMC free article] [PubMed] [CrossRef] [Google Scholar]6. Pisinger C., Døssing M. A systematic review of health effects of electronic cigarettes. Preventive Medicine. 2014;69:248–260. doi: 10.1016/j.ypmed.2014.10.009. [PubMed] [CrossRef] [Google Scholar]7. Rodrigues T., Deal E., Nugent K., Payne J. D. Electronic cigarettes and lung toxicity. The Southwest Respiratory and Critical Care Chronicles. 2017;5(16) doi: 10.12746/swrccc.v5i19.394. [CrossRef] [Google Scholar]8. Thota D., Latham E. Case report of electronic cigarettes possibly associated with eosinophilic pneumonitis in a previously healthy active-duty sailor. The Journal of Emergency Medicine. 2014;47(1):15–17. doi: 10.1016/j.jemermed.2013.09.034. [PubMed] [CrossRef] [Google Scholar]9. Flower M., Nandakumar L., Singh M., Wyld D., Windsor M., Fielding D. Respiratory bronchiolitis-associated interstitial lung disease secondary to electronic nicotine delivery system use confirmed with open lung biopsy. Respirology Case Reports. 2017;5(3) doi: 10.1002/rcr2.230. [PMC free article] [PubMed] [CrossRef] [Google Scholar]10. Lara A. R., Schwarz M. I. Diffuse alveolar hemorrhage. CHEST. 2010;137(5):1164–1171. doi: 10.1378/chest.08-2084. [PubMed] [CrossRef] [Google Scholar]11. Park M. S. Diffuse alveolar hemorrhage. Tuberculosis and Respiratory Diseases. 2013;74(4):151–162. doi: 10.4046/trd.2013.74.4.151. [PMC free article] [PubMed] [CrossRef] [Google Scholar]12. Grassin F., André M., Rallec B., Combes E., Vinsonneau U., Paleiron N. Hémorragie alvéolaire fatale après bang de cannabisFatal alveolar haemorrhage following a “bang” of cannabis. Revue des Maladies Respiratoires. 2011;28(7):919–923. doi: 10.1016/j.rmr.2011.05.005. [PubMed] [CrossRef] [Google Scholar]13. Dushay K. M., Evans S. K., Ghimire S., Liu J. Cocaine-induced diffuse alveolar hemorrhage: A case report and review of the literature. Rhode Island Medical Journal (2013) 2016;99(8):34–36. [PubMed] [Google Scholar]14. Shields P. G., Berman M., Brasky T. M., et al. A review of pulmonary toxicity of electronic cigarettes in the context of smoking: A focus on inflammation. Cancer Epidemiology Biomarkers & Prevention. 2017;26(8):1175–1191. doi: 10.1158/1055-9965.EPI-17-0358. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Articles from Case Reports in Pulmonology are provided here courtesy of Hindawi Limited
Copyright and License Information
Copyright © 2018 Michael Agustin et al.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.